Foundayo

Foundayo (orforglipron) is Eli Lilly's once-daily oral GLP-1 receptor agonist, FDA-approved on April 1, 2026 for chronic weight management in adults with obesity or with overweight plus a weight-related comorbidity [6]. It is the first non-peptide small-molecule GLP-1 agonist cleared in the United States, which matters because every commercially meaningful GLP-1 drug before it has been an injected peptide or, in Rybelsus's case, a fragile peptide pill that demands fasting and timed water. Orforglipron is a normal tablet taken with food, no fasting, no needles, no cold chain. Foundayo launched at a WAC list price of $649 per month (roughly $7,788 per year) on April 9, 2026, with a LillyDirect self-pay program starting at $149 per month for the starter dose [15]. The drug itself has no separately reported revenue yet given the April 2026 launch. Lilly recorded roughly $65.2 billion in total 2025 company revenue, and Wall Street is pricing Foundayo plus the broader orforglipron program as the next pillar of an incretin franchise that already moves tens of billions through Mounjaro and Zepbound [8]. The Phase 3 type 2 diabetes filing supported by the ACHIEVE program is the next near-term regulatory milestone [1].

Foundayo cleared FDA review on April 1, 2026 as a full approval under NDA 220934, not accelerated [6]. The approval came 50 days after filing under the FDA's National Priority Voucher program, well ahead of the original PDUFA date of January 20, 2027. The label is the standard chronic weight management framing: combination with a reduced-calorie diet and increased physical activity, in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbid condition. The drug carries the GLP-1 class boxed warning for risk of thyroid C-cell tumors based on rodent carcinogenicity data that has accompanied every GLP-1 agonist since exenatide, and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [6]. No generic ANDA has been filed; orforglipron is composition-of-matter protected with new chemical entity exclusivity running five years from approval, plus formulation and method-of-use patents extending into the early-to-mid 2030s. Type 2 diabetes is the next regulatory submission. Lilly has signaled an sNDA submission in 2026 based on the ACHIEVE program, but the specific filing date and PDUFA target have not been publicly disclosed [1]. Supply is the variable Lilly investors watch most closely. The company poured roughly $50 billion into manufacturing capacity across 2024-2026 to avoid the Mounjaro and Zepbound shortages that defined 2023, and orforglipron's tablet format sidesteps the sterile fill-finish bottleneck that constrained the injectables. Foundayo is on market and shipping.

GLP-1 (glucagon-like peptide 1) is a hormone the gut releases within minutes of a meal. It does three useful things at once: it tells the pancreas to release insulin to handle the incoming sugar, it slows how quickly the stomach empties so food trickles into the small intestine, and it signals the brain's appetite circuits that you are full. People with type 2 diabetes and obesity have blunted GLP-1 responses, so giving them a longer-lasting agonist restores the satiety and glucose control the body should already be doing on its own. Every clinically meaningful GLP-1 drug before orforglipron has been a peptide, a chain of amino acids that the gut would chew up before absorption. That is why semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide, and exenatide are injections. Novo's Rybelsus is an oral peptide rescued by a permeation enhancer, but it must be taken on an empty stomach with 4 ounces of water and a 30-minute wait before eating, a regimen patients routinely fail. Orforglipron is structurally different. It is a small molecule, roughly the size of a typical pill compound, that survives the gut intact and binds the same GLP-1 receptor (GLP1R) on pancreatic beta cells, gut cells, and appetite neurons in the hypothalamus. The downstream cAMP signaling cascade is identical to what an injected peptide triggers, so the biology is unchanged, but the delivery is finally simple. GLP-1R itself is one of the most validated drug targets in medicine, with multiple approved agonists across two decades. Orforglipron's novelty is the delivery modality (oral small molecule), not the target.

Lilly ran two parallel Phase 3 programs: ATTAIN for obesity (with sub-studies in hypertension, sleep apnea, weight maintenance, and cardiovascular safety) and ACHIEVE for type 2 diabetes. ATTAIN-1 (NCT06066698, n=3,127), published in the New England Journal of Medicine, delivered a 12.4 percent mean body weight reduction at 72 weeks at the highest dose versus placebo, with 59.6 percent of participants achieving at least 10 percent loss and 39.6 percent achieving at least 15 percent loss [13]. That is the single number to anchor against the injectable benchmarks. ATTAIN-MAINTAIN (NCT06584916) was not a continuation of orforglipron-driven weight loss. It was a first-of-kind switch trial: patients from SURMOUNT-5 who had already lost weight on injectable tirzepatide or semaglutide were re-randomized to switch to oral orforglipron or to placebo for 52 weeks of maintenance [7]. In the tirzepatide-prior arm, orforglipron-treated patients preserved 74.7 percent of their prior weight reduction versus 49.2 percent on placebo; in the semaglutide-prior arm, orforglipron preserved 79.3 percent versus 37 percent on placebo. The clinical meaning is that patients can transition off injectables onto the oral drug without significant rebound, which is the commercial bridge for the injectable-treated population. ACHIEVE-5 (n=546), published in JAMA in 2026, added orforglipron to titrated insulin glargine in patients with type 2 diabetes inadequately controlled on basal insulin alone. HbA1c fell 1.58 percent, 1.88 percent, and 1.82 percent in the 3 mg, 12 mg, and 36 mg arms respectively versus 0.77 percent on placebo, with body weight falling 2.7 to 6.1 percent versus a 0.6 percent gain on placebo; up to 70 percent of orforglipron patients reached HbA1c below 7 percent [1]. ACHIEVE-4 (NCT05803421) was the dedicated cardiovascular safety trial in T2D patients with elevated CV risk. It met non-inferiority to insulin glargine on MACE-4 (HR 0.84, 95 percent CI 0.59 to 1.20), and in a pre-planned analysis showed a 57 percent reduction in all-cause mortality versus insulin glargine (HR 0.43, nominal p=0.002) [14]. Network meta-analyses comparing oral and subcutaneous GLP-1 monoagonists for cardiometabolic outcomes have placed orforglipron in the same general effect range as semaglutide for HbA1c reduction, with a tolerability profile that fits the class [5]. The safety story is the GLP-1 story. Nausea, vomiting, diarrhea, and constipation are common, dose-dependent, mostly front-loaded, and largely resolve with slow titration. A 2026 network meta-analysis specifically of orforglipron's gastrointestinal safety found event rates in line with injectable peptides, with no signal that the small-molecule chemistry introduces a new toxicity class [2]. Pharmacokinetic work confirmed bioequivalence between the tablet and the capsule formulations used in trials, which simplifies commercial launch [4]. The 2025 CVOT Summit Report flagged orforglipron as the leading oral candidate in the cardiovascular-kidney-metabolic continuum [3].

Competition splits into two tiers. The first is the injectable incumbents already in market. Lilly's own Zepbound (tirzepatide, a dual GIP/GLP-1 agonist) and Novo's Wegovy (semaglutide) together generated tens of billions in 2025 sales and set the obesity efficacy bar at roughly 15 percent (semaglutide) and up to 22 percent (tirzepatide) body weight reduction. Orforglipron's 12.4 percent at 72 weeks lands below both injectable benchmarks. That is the honest read on efficacy. The strategic case is not that orforglipron beats injectables on the scale, it is that the addressable obesity population numbers in the hundreds of millions globally, the injectable-averse and primary-care-treated and payer-limited segment is enormous, and that segment is only reachable with a pill. ATTAIN-MAINTAIN also opens a step-down play: a patient can lose weight on injectable tirzepatide or semaglutide and then transition to the cheaper-to-manufacture oral for maintenance without losing most of the gain. The second tier is oral GLP-1 competition. Novo's Rybelsus has been on market since 2019 but the fasting protocol has held it back. Novo's oral amycretin and higher-dose oral semaglutide are advancing. Pfizer's danuglipron program was discontinued on April 14, 2025 after a single case of drug-induced liver injury in a dose-optimization study, taking Pfizer effectively out of the oral GLP-1 race for several years [11]. Roche/Carmot's CT-996 is mid-stage. Structure Therapeutics' aleniglipron (formerly GSBR-1290) is the closest pure competitor and the threat to watch, a small-molecule oral GLP-1 advancing through pivotal development [12]. Patent runway extends into the early-to-mid 2030s under composition-of-matter and method-of-use claims, with NCE exclusivity blocking ANDAs for five years from approval. Because orforglipron is a small molecule, eventual generic erosion will come from ANDAs rather than biosimilars, but that is still years away.

The 78.3 percent probability of success score reflects an unusual position: a drug that has already cleared its primary regulatory hurdle and now faces lifecycle expansion rather than de novo approval risk. The largest single distortion in the model is the target novelty factor, which was scored 0.70x negative on the rationale that no approved drugs exist for this target. That is wrong. GLP-1R is one of the most validated targets in medicine, with at least six approved agonists (semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, albiglutide). Orforglipron's novelty is delivery modality (oral small molecule), not target biology. Corrected to neutral, the score moves materially higher even before factoring in the April 1, 2026 approval itself. The 1.30x sponsor track record reflects Lilly's near-perfect Phase 3 conversion in metabolic disease over the past decade. Prior phase success should also flip positive given the successful Phase 2 GZGD program in T2D that read out cleanly into Phase 3. Catalysts over the next 12 to 18 months: the type 2 diabetes sNDA filing (target 2026, PDUFA not yet disclosed), the ATTAIN-Hypertension readout, the Phase 3 knee osteoarthritis trial (NCT07153471) [9], the Phase 3 stress urinary incontinence trial (NCT07202884) [10], the first two quarters of meaningful Foundayo sales disclosure on Lilly's earnings calls, and payer formulary placement (Part D coverage and commercial tier positioning will drive the ramp more than any clinical milestone over the next 18 months). What would change the thesis: a real-world hepatotoxicity signal of the kind that killed danuglipron, a manufacturing-scale shortfall, or aleniglipron Phase 3 data that matches orforglipron on efficacy with cleaner GI tolerability. Absent those, Lilly's commercial machinery and the simple pill format point to a multi-billion-dollar franchise within 24 months of launch, with the longer-tail prize being a formal cardiovascular outcomes label built from ACHIEVE-4 and follow-on CV data.

target_novelty factor corrected from 0.70x negative to 1.0x neutral: GLP-1R is a validated target with multiple approved agonists; orforglipron's novelty is delivery modality, not target. prior_phase_success updated to positive based on Phase 2 GZGD readout. competitive_density updated to slight negative to reflect the dense oral GLP-1 field. patent_expiry populated to 2035 estimate based on NCE plus composition-of-matter. wac_annual_usd populated from April 2026 launch list price of $649/month.

Orforglipron is FDA-approved (FOUNDAYO, 2026-04-01). BioCosm's model estimates a drug's first FDA approval, which has already happened here, so no probability is shown - any current trial is a new-indication study.